InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Anti-HLA Class II Control | False Positive B-Cells Crossmatch after Prior Rituximab Exposure of the Kidne... | 2016 | Case Rep Transplant. | Desoutter J. et al. | DOI: 10.1155/2016/4534898 |
| N-Glycolyl-MDP | Signaling through NOD-2 and TLR-4 bolsters the T cell priming capability of d... | 2016 | Sci Rep. | Khan N. et al. | DOI: 10.1038/srep19084 |
| CL075 (3M002) | Extracellular RNA liberates tumor necrosis factor-α to promote tumor cell tra... | 2013 | Cancer Res. | Fischer S. et al. | DOI: 10.1158/0008-5472.CAN-12-4657 |
| HEK-Blue™ Null1 Cells | Investigations on the molecular mode of action of the novel immunostimulator ... | 2017 | Mol Immunol. | Ilg T. | DOI: 10.1016/j.molimm.2017.07.013 |
| Anti-HLA Class II Control | Production and characterization of chimeric anti-HLA monoclonal antibodies ta... | 2013 | J Immunol Methods. | Congy-Jolivet N. et al. | DOI: 10.1016/j.jim.2013.01.007 |
| N-Glycolyl-MDP | HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuv... | 2016 | PLoS One. | Apostólico Jde S. et al. | DOI: 10.1371/journal.pone.0145637 |
| HEK-Blue™ Null1 Cells | TLR9 activation suppresses inflammation in response to Helicobacter pylori in... | 2016 | Am J Physiol Gastrointest Liver Physiol. | Varga M.G. et al. | DOI: 10.1152/ajpgi.00175.2016 |
| Anti-murine TLR2 (clone T2.5) Detection and Neutralizing mAb | A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epi... | 2017 | Am J Pathol. | Feng L. et al. | DOI: 10.1016/j.ajpath.2017.06.015 |
| FLA-ST (Standard or Ultrapure) | The COP II adaptor protein TMED7 is required to initiate and mediate the deli... | 2014 | Sci Signal. | Liaunardy-Jopeace A. et al. | DOI: 10.1126/scisignal.2005275 |
| Zymosan | Local TNFR1 Signaling Licenses Murine Neutrophils for Increased TLR-Dependent... | 2017 | J Immunol. | Deguine J. et al. | DOI: 10.4049/jimmunol.1601465 |
| Imiquimod VacciGrade™ (R837) | Early type I Interferon response induces upregulation of human β-defensin 1 d... | 2017 | PLoS One. | Corleis B. et al. | DOI: 10.1371/journal.pone.0173161 |
| Human TLR4 Reporter HEK293 Cells (NF-κB) | Human SR-BI and SR-BII Potentiate Lipopolysaccharide-Induced Inflammation and... | 2016 | J Immunol. | Baranova I.N. et al. | DOI: 10.4049/jimmunol.1501709 |
| Normocin® - Antimicrobial Reagent | The Bacteroidales produce an N-acylated derivative of glycine with both chole... | 2017 | Sci Rep. | Lynch A. et al. | DOI: 10.1038/s41598-017-13774-6 |
| ODN 2006 (ODN 7909) | A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. | 2017 | J Clin Invest. | Sindhava V.J. et al. | DOI: 10.1172/JCI89931 |
| Alhydrogel® adjuvant 2% | A recombinant protein of Salmonella Typhi induces humoral and cell-mediated i... | 2017 | Vaccine. | Das S. et al. | DOI: 10.1016/j.vaccine.2017.07.035 |
| Human TLR2 Reporter HEK293 Cells (NF-κB) | Toll-like receptor mediated activation is possibly involved in immunoregulati... | 2017 | PLoS One. | Kiewiet M.B. et al. | DOI: 10.1371/journal.pone.0178191 |
| R848 (Resiquimod) | Tissue-Resident Macrophages Are Locally Programmed for Silent Clearance of Ap... | 2017 | Immunity. | Roberts A.W. et al. | DOI: 10.1016/j.immuni.2017.10.006 |
| C12-iE-DAP | NOD1 activators link innate immunity to insulin resistance. | 2011 | Diabetes | Schertzer J.D. et al. | DOI: 10.2337/db11-0004 |
| R848 VacciGrade™ | Enhanced stimulation of human tumor-specific T cells by dendritic cells matur... | 2017 | Cancer Immunol Immunother. | Lövgren T. et al. | DOI: 10.1007/s00262-017-2029-4 |
| CL264 | TLR7 promotes tumor progression, chemotherapy resistance and poor clinical ou... | 2014 | Cancer Res. | Chatterjee S. et al. | DOI: 10.1158/0008-5472.CAN-13-2698 |